Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Exicure (NASDAQ:XCUR) Head-To-Head Review

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Exicure (NASDAQ:XCUR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Aurinia Pharmaceuticals and Exicure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	3	1	2.71
Exicure	1	0	0	0	1.00

Aurinia Pharmaceuticals presently has a consensus target price of $17.75, indicating a potential upside of 6.61%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Exicure.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Exicure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.83	$287.20 million	$2.29	7.27
Exicure	$500,000.00	13.23	-$4.95 million	($1.32)	-0.77

Aurinia Pharmaceuticals has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Aurinia Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.64, meaning that its share price is 264% more volatile than the S&P 500.

Profitability

This table compares Aurinia Pharmaceuticals and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Exicure	N/A	-237.91%	-61.98%

Summary

Aurinia Pharmaceuticals beats Exicure on 10 of the 14 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.